ALNY

NASDAQ · Biotechnology

Alnylam Pharmaceuticals Inc

Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$286.98

-6.47 (-2.20%)

As of May 16, 1:05 AM ET ·

Analyst Consensus

Strong Buy

Analysts

Very High

Coverage

Buy 27 75%

Hold 9 25%

Sell 0 0%

Price Target

Analyst Price Target -64.3% upside

Low Target $75.08

Average Target $102.31

High Target $108.98

Current Price $286.98

Current
$286.98

Target
$102.31

$75.08 $102.31 avg $108.98

Scenario Analysis

Bear Case

$75.08

-73.8%

Low target

Base Case

$102.31

-64.3%

Avg target

Bull Case

$108.98

+-62.0%

High target

Risk/Reward

0.8x

Unfavorable

Price in Context

52-Week High

$495.55

-42.1% from high

52-Week Low

$261.85

+9.6% from low

50-Day SMA

$371.56

-22.8% vs SMA

200-Day SMA

$388.35

-26.1% vs SMA

RSI (14)

46.4

Neutral

Target vs 52W High

$102.31

-79.4% vs high

Peer Consensus — Biotechnology

Stock	Consensus	Analysts	Buy %	Target	Upside
ABBV Abbvie Inc	Strong Buy	40	75%	$257.58	+22.4%
AMGN Amgen Inc	Hold	44	48%	$190.87	-41.5%
GILD Gilead Sciences Inc	Strong Buy	39	79%	$362.68	+179.9%
VRTX Vertex Pharmaceuticals Inc	Strong Buy	39	79%	$438.34	+0.3%
REGN Regeneron Pharmaceuticals	Strong Buy	38	79%	$76.80	-89.0%
ALNY Alnylam Pharmaceuticals Inc	Strong Buy	36	75%	$102.31	-64.3%
RVMD Revolution Medicines Inc	Strong Buy	27	96%	$114.11	-21.7%
BIIB Biogen Inc	Buy	43	56%	$91.45	-52.6%